Senior Editor, OncLive®
Courtney Marabella joined the MJH Life Sciences team in 2021 and is Senior Editor for OncLive®. Prior to joining the company she worked as the Audience Development Editor for the Asbury Park Press, part of the USA Today Network. Email: cmarabella@onclive.com
Phase 3 OVAL Trial of VB-111 in Platinum-Resistant Ovarian Cancer Gets Green Light to Continue
February 24th 2021February 24, 2021 - An independent data safety monitoring committee has not observed any safety issues with the phase 3 OVAL trial examining VB-111 in patients with platinum-resistant ovarian cancer, and as such, has recommended that the trial continue as planned.
Read More
130 Centers, Organizations Call for Priority Access to a COVID-19 Vaccine for Patients With Cancer
February 19th 2021February 18, 2021 - One hundred and thirty organizations, cancer centers, and other institutions sent a letter to President Joe Biden and his administration, as well as other leading public health officials at state health departments to underscore the need to provide patients with cancer and survivors of cancer with priority access to a coronavirus disease 2019 vaccine.
Read More
Zanidatamab Shows Durable Antitumor Activity in HER2-Expressing Gastroesophageal Adenocarcinoma
February 15th 2021February 15, 2021 - Zanidatamab demonstrated promising antitumor activity with favorable tolerability in patients with HER2-expressing gastroesophageal adenocarcinoma that has progressed following previous therapies, including HER2-targeted agents.
Read More
Cabozantinib Significantly Prolongs PFS Over Sunitinib in Papillary RCC
February 14th 2021February 13, 2021 - Cabozantinib resulted in a statistically significant and clinically meaningful prolongation of progression-free survival compared with sunitinib in patients with metastatic papillary renal cell carcinoma.
Read More
Borghaei Breaks Down Choices in Immunotherapy Approaches in Lung Cancer
February 8th 2021With the emergence of multiple immunotherapy approaches in recent years, the decision of whether to use a single agent, to pair it with chemotherapy, or to pair it with another immunotherapy agent has come to the forefront of treatment.
Read More
Mobocertinib Shows Encouraging ORR in EGFR Exon 20–Mutant Advanced NSCLC
January 30th 2021January 29, 2021 — Mobocertinib (formerly TAK-788) demonstrated clinically meaningful benefit and a manageable safety profile in previously treated patients with metastatic non–small cell lung cancer who have EGFR exon 20 insertion mutations.
Read More
NeoADAURA Trial Slated to Examine Neoadjuvant Osimertinib in Resectable EGFR+ NSCLC
January 28th 2021January 28, 2021 - The NeoADAURA trial will evaluate the safety and efficacy of neoadjuvant osimertinib, as a single agent or in combination with platinum-based chemotherapy compared with chemotherapy alone, in patients with resectable, stage II-IIIB non–small cell lung cancer whose tumors harbor EGFR mutations.
Read More
Onvansertib Plus FOLFIRI/Bevacizumab Shows Preliminary Efficacy, Tolerability in Second-Line mCRC
January 27th 2021January 27, 2021 - The combination of the polo-like kinase 1 inhibitor, onvansertib, with FOLFIRI and bevacizumab was found to have preliminary activity and favorable tolerability when used as a second-line treatment for patients with KRAS-mutated metastatic colorectal cancer.
Read More
Shorter Course of SBRT Proves Safe, Effective in High-Risk Prostate Cancer
January 27th 2021January 27, 2021 — A shorter course of stereotactic body radiotherapy has been shown to have encouraging efficacy with favorable toxicity when used in patients with high-risk prostate cancer in a multi-institutional, international setting.
Read More
Postoperative MRD Positivity Linked With Reduced RFS in CRC
January 26th 2021January 26, 2021 — Patients with colorectal cancer who had molecular residual disease positivity immediately after surgery were found to have a high risk of disease recurrence and longitudinal monitoring increased the predictive power of circulating tumor DNA.
Read More
NCCN Releases COVID-19 Vaccination Guidance for Patients With Cancer
January 22nd 2021All patients with active cancer, or with active, recent, or planned cancer treatment, should be considered highest priority to receive one of the coronavirus disease 2019 vaccines that have been granted emergency use authorization from the FDA.
Read More